相似文献
1
Systematic editing of synthetic RIG-I ligands to produce effective antiviral and anti-tumor RNA immunotherapies.
Nucleic Acids Res. 2018 Nov 2;46(19):10533. doi: 10.1093/nar/gky819.
2
Systematic editing of synthetic RIG-I ligands to produce effective antiviral and anti-tumor RNA immunotherapies.
Nucleic Acids Res. 2018 Feb 28;46(4):1635-1647. doi: 10.1093/nar/gky039.
3
Sequence-Specific Modifications Enhance the Broad-Spectrum Antiviral Response Activated by RIG-I Agonists.
J Virol. 2015 Aug;89(15):8011-25. doi: 10.1128/JVI.00845-15. Epub 2015 May 27.
4
Approaching the RNA ligand for RIG-I?
Immunol Rev. 2009 Jan;227(1):66-74. doi: 10.1111/j.1600-065X.2008.00724.x.
5
PAMPer and tRIGer: ligand-induced activation of RIG-I.
Trends Biochem Sci. 2011 Jun;36(6):314-9. doi: 10.1016/j.tibs.2011.03.003. Epub 2011 Apr 14.
6
RIG-I is responsible for activation of type I interferon pathway in Seneca Valley virus-infected porcine cells to suppress viral replication.
Virol J. 2018 Oct 23;15(1):162. doi: 10.1186/s12985-018-1080-x.
7
RIG-I is a key antiviral interferon-stimulated gene against hepatitis E virus regardless of interferon production.
Hepatology. 2017 Jun;65(6):1823-1839. doi: 10.1002/hep.29105. Epub 2017 May 3.
8
Synthetic double-stranded RNA induces retinoic acid-inducible gene-I in mouse osteoblastic cells.
Mol Med Rep. 2008 Nov-Dec;1(6):833-6. doi: 10.3892/mmr_00000036.
9
[Cell type specific involvement of RIG-I in antiviral responses].
Nihon Rinsho. 2006 Jul;64(7):1244-7.
10
DDX60 Is Involved in RIG-I-Dependent and Independent Antiviral Responses, and Its Function Is Attenuated by Virus-Induced EGFR Activation.
Cell Rep. 2015 May 26;11(8):1193-207. doi: 10.1016/j.celrep.2015.04.047. Epub 2015 May 14.
引用本文的文献
1
Intratumoral delivery of RIG-I agonist SLR14 induces robust antitumor responses.
J Exp Med. 2019 Dec 2;216(12):2854-2868. doi: 10.1084/jem.20190801. Epub 2019 Oct 10.
Zotero 插件